Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 7 |
| List of Tables | 7 | 1 |
| List of Figures | 8 | 1 |
| Introduction | 9 | 1 |
| Global Markets Direct Report Coverage | 9 | 1 |
| Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) Overview | 10 | 1 |
| Therapeutics Development | 11 | 4 |
| Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) Products under Development by Stage of Development | 11 | 1 |
| Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) Products under Development by Therapy Area | 12 | 1 |
| Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) Products under Development by Indication | 13 | 2 |
| Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) Pipeline Products Glance | 15 | 2 |
| Late Stage Products | 15 | 1 |
| Early Stage Products | 16 | 1 |
| Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) Products under Development by Companies | 17 | 5 |
| Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) Products under Development by Universities/Institutes | 22 | 2 |
| Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) Therapeutics Assessment | 24 | 5 |
| Assessment by Monotherapy/Combination Products | 24 | 1 |
| Assessment by Mechanism of Action | 25 | 1 |
| Assessment by Route of Administration | 26 | 2 |
| Assessment by Molecule Type | 28 | 1 |
| Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) Companies Involved in Therapeutics Development | 29 | 15 |
| Acetylon Pharmaceuticals, Inc. | 29 | 2 |
| Chong Kun Dang Pharmaceutical Corp. | 31 | 1 |
| HitGen LTD | 32 | 1 |
| Kancera AB | 33 | 1 |
| Karus Therapeutics Limited | 34 | 1 |
| Lycera Corp. | 35 | 1 |
| Merck &Co., Inc. | 36 | 1 |
| Millennium Pharmaceuticals, Inc. | 37 | 1 |
| OncoHoldings, Inc. | 38 | 1 |
| Quimatryx, S.L. | 39 | 1 |
| Sigma-Tau S.p.A. | 40 | 1 |
| SK Biopharmaceuticals Co., Ltd. | 41 | 1 |
| Takeda Pharmaceutical Company Limited | 42 | 1 |
| TetraLogic Pharmaceuticals | 43 | 1 |
| Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) Drug Profiles | 44 | 44 |
| ACY-241 Drug Profile | 44 | 2 |
| ACY-738 Drug Profile | 46 | 1 |
| ACY-775 Drug Profile | 47 | 1 |
| C-1A Drug Profile | 48 | 1 |
| CKD-506 Drug Profile | 49 | 1 |
| CKD-L Drug Profile | 50 | 1 |
| Drugs to Inhibit HDAC6 for Oncology Drug Profile | 51 | 1 |
| HG-3001 Drug Profile | 52 | 1 |
| IKH-12 Drug Profile | 53 | 1 |
| KA-2507 Drug Profile | 54 | 1 |
| KAN-0439221 Drug Profile | 55 | 1 |
| KAN-439782 Drug Profile | 56 | 1 |
| KAR-3000 Drug Profile | 57 | 1 |
| N-140 Drug Profile | 58 | 1 |
| ONCO-101 Drug Profile | 59 | 1 |
| QTX-100 Drug Profile | 60 | 1 |
| QTX-102 Drug Profile | 61 | 1 |
| QTX-125 Drug Profile | 62 | 1 |
| remetinostat Drug Profile | 63 | 2 |
| ricolinostat Drug Profile | 65 | 7 |
| Small Molecule to Inhibit HDAC1, HDAC3 and HDAC6 for Lung Adenocarcinoma Drug Profile | 72 | 1 |
| Small Molecule to Inhibit HDAC6 Drug Profile | 73 | 1 |
| Small Molecule to Inhibit HDAC6 for Charcot-Marie-Tooth Disease Drug Profile | 74 | 1 |
| Small Molecule to Inhibit HDAC6 for Oncology Drug Profile | 75 | 1 |
| Small Molecule to Inhibit HDAC6 for Sepsis Drug Profile | 76 | 1 |
| Small Molecules to Inhibit HDAC-6 for Immunology, Oncology and Genetic Disorders Drug Profile | 77 | 1 |
| Small Molecules to Inhibit HDAC6 for Autoimmune Diseases Drug Profile | 78 | 1 |
| Small Molecules to Inhibit HDAC6 for Neurodegenerative, Autoimmune and Inflammatory Diseases Drug Profile | 79 | 1 |
| Small Molecules to Inhibit HDAC6 for Oncology Drug Profile | 80 | 1 |
| Small Molecules to Inhibit HDAC6 for Oncology and Immunology Drug Profile | 81 | 1 |
| Small Molecules to Inhibit Histone Deacetylase 6 for Oncology Drug Profile | 82 | 1 |
| ST-3595 Drug Profile | 83 | 1 |
| vorinostat Drug Profile | 84 | 4 |
| Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) Dormant Projects | 88 | 2 |
| Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) Featured News &Press Releases | 90 | 19 |
| Jun 03, 2016: Acetylon Collaborators Publish ASCO Abstracts Demonstrating Immunomodulatory Properties of Ricolinostat in Preclinical Melanoma Models | 90 | 1 |
| Apr 20, 2016: Acetylon Announces the Presentation of Preclinical Data at AACR Supporting the Use of Selective HDAC6 Inhibition to Modulate Chronic Lymphocytic Leukemia (CLL) Immunobiology | 91 | 1 |
| Dec 07, 2015: Acetylon Presents Data from Three Phase 1b Studies of Ricolinostat (ACY-1215) for the Treatment of Lymphoma and Multiple Myeloma | 92 | 2 |
| Dec 07, 2015: Acetylon Presents Data on the use of HDAC 6 Inhibitors Ricolinostat and ACY-241 in Combination with Pomalidomide for the Treatment of Multiple Myeloma | 94 | 2 |
| Nov 06, 2015: Acetylon's Oral Selective HDAC6 Inhibitor ACY-241 Enhances Anti-tumor Activity of Paclitaxel in Preclinical Solid Tumor Models | 96 | 2 |
| Nov 02, 2015: TetraLogic Announces the Opening of an IND for SHAPE Gel in Alopecia Areata | 98 | 1 |
| Jun 15, 2015: Acetylon Pharmaceuticals Presented Positive Preliminary Data from Phase 1b/2 Trial of Ricolinostat in Combination with Pomalyst as Potential Oral Treatment for Patients with Multiple Myeloma | 98 | 1 |
| Apr 22, 2015: Acetylon Presents Data on Synergistic Activity of Selective HDAC6 Inhibition in Preclinical Models of Multiple Myeloma and Mantle Cell Lymphoma at the American Association for Cancer Research Annual Meeting | 99 | 1 |
| Jan 21, 2015: Acetylon Presents at the Wells Fargo Celgene Partnership Forum | 100 | 1 |
| Dec 18, 2014: TetraLogic Announces Initiation of a Randomized Phase 2 Clinical Trial of SHAPE in Subjects With Cutaneous T-Cell Lymphoma | 101 | 1 |
| Dec 09, 2014: Acetylon Pharmaceuticals Announces Ricolinostat Continues to Demonstrate Clinically Meaningful and Durable Disease Response Rates in Phase 1b Combination Studies in Multiple Myeloma | 101 | 2 |
| Dec 04, 2014: Acetylon Pharmaceuticals Initiates Phase 2 Study of Ricolinostat (ACY-1215) in Combination with Pomalyst | 103 | 1 |
| Dec 01, 2014: Acetylon s Selective HDAC Inhibitors To Be Featured In Multiple Presentations Of Positive Clinical And Preclinical Data At The 56th ASH Annual Meeting And Exposition | 103 | 4 |
| Jun 13, 2014: Acetylon Pharmaceuticals Reports Ricolinostat (ACY-1215) is Active and Well-tolerated in Ongoing Phase 1b Studies in Patients with Refractory Multiple Myeloma at the 19th Congress of the EHA | 107 | 1 |
| May 28, 2014: TetraLogic Pharmaceuticals to Present Data From Its Clinical Investigation of SHAPE at the Annual American Society of Clinical Oncology Meeting | 108 | 1 |
| Appendix | 109 | 2 |
| Methodology | 109 | 1 |
| Coverage | 109 | 1 |
| Secondary Research | 109 | 1 |
| Primary Research | 109 | 1 |
| Expert Panel Validation | 109 | 1 |
| Contact Us | 109 | 1 |
| Disclaimer | 110 | 1 |